Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032 Jul 1, 2025 09:50AM
Cybin Inc (CYBN) to Acquire Small Pharma Inc. Aug 28, 2023 10:47AM
Cybin to Acquire Small Pharma Inc. Aug 28, 2023 10:47AM
Cybin Inc (CYBN) Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial Aug 17, 2023 07:30AM
Cybin Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial Aug 17, 2023 07:30AM
View Older Stories

Aug 15, 2023 07:52AM Cybin Inc (CYBN) Granted US Patent Covering Proprietary Deuterated Psilocybin Analog in CYB003
Aug 15, 2023 07:52AM Cybin Announces Grant of U.S. Patent Covering Proprietary Deuterated Psilocybin Analog in its CYB003 Program
Aug 14, 2023 07:30AM Cybin Reports First Quarter Financial Results and Recent Business Highlights
Aug 2, 2023 07:30AM Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder
Jul 27, 2023 07:30AM Cybin to Participate in the Canaccord Genuity 43rd Annual Growth Conference
Jul 26, 2023 07:30AM Cybin Partners With Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder
Jul 24, 2023 07:55AM Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder
Jul 20, 2023 05:02PM Cybin Inc (CYBN) Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain
Jul 20, 2023 05:01PM Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain
Jul 20, 2023 08:00AM Kernel's Revolutionary Neuroimaging Technology, Flow1, Validated in Published Feasibility Study on Measuring Psychedelic Effects
Jul 12, 2023 07:31AM Cybin (CYBN) Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT
Jul 12, 2023 07:30AM Cybin Announces the Development of a Scalable Psychedelic Facilitation Training Program, EMBARKCT
Jun 30, 2023 07:30AM Cybin to Participate in PSYCH Symposium London 2023
Jun 29, 2023 05:00PM Cybin Inc (CYBN) Announces Appointment of Aaron Bartlone as Chief Operating Officer
Jun 29, 2023 05:00PM Cybin Inc. Announces Appointment of Aaron Bartlone as Chief Operating Officer
Jun 27, 2023 05:00PM Cybin Inc. Reports Fiscal Year 2023 Financial Results and Recent Business Highlights
Jun 27, 2023 07:30AM Cybin Announces Appointment of Sanford R. Climan as Strategic Advisor
Jun 21, 2023 07:30AM Cybin to Participate in the 2023 MAPS Psychedelic Science Conference
Jun 15, 2023 07:30AM Cybin to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Jun 8, 2023 07:31AM Cybin Inc (CYBN) Provides Corporate Update
Jun 8, 2023 07:30AM Cybin Inc. Provides Corporate Update
Jun 5, 2023 07:30AM Cybin Announces Scientific Management Transition Following Achievement of Final Adelia Milestones
Jun 1, 2023 07:30AM Cybin to Present at the Jefferies Healthcare Conference
May 30, 2023 05:46PM Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund
May 24, 2023 07:30AM Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial
May 9, 2023 07:30AM Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial
Apr 28, 2023 08:00AM  Cybin to Participate at the 26th Annual Milken Institute Global Conference
Apr 12, 2023 07:31AM Cybin Inc (CYBN) Announces EMBARK Open Access
Apr 12, 2023 07:30AM Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy
Jun 21, 2021 07:00AM CEO Presenting on the First Emerging Growth / Investors Hub Joint Conference on June 23. Register Now
Nov 10, 2020 10:45AM Cybin Goes Public on NEO Exchange
View Older Stories